CLINIGEN HLTHCARE
SpecialtyCLINIGEN HLTHCARE is a specialty pharmaceutical company focused on Immunology, Infectious Disease.
CLINIGEN HLTHCARE's Key Drugs
CLINIGEN HLTHCARE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
CLINIGEN HLTHCARE's Recent FDA Approvals
New NDA/BLA approvals for CLINIGEN HLTHCARE over the last two years — novel drugs only, excluding generics and label supplements.
CLINIGEN HLTHCARE's Therapeutic Areas
CLINIGEN HLTHCARE's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CLINIGEN HLTHCARE's Top Competitors
CLINIGEN HLTHCARE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CLINIGEN HLTHCARE Pipeline Snapshot
Active clinical trials for CLINIGEN HLTHCARE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1991-09-27
- Latest
- 2020-10-28
- Applications
- 1